Cognition Therapeutics, Inc. (CGTX) vs ImmuCell Corporation (ICCC)

Cognition Therapeutics, Inc. and ImmuCell Corporation are both Biotechnology companies. Cognition Therapeutics, Inc. and ImmuCell Corporation are of similar size ($90.7M and $90.6M). Cognition Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; ImmuCell Corporation trades at 117×. ImmuCell Corporation has the higher net margin (2.57% vs 0.00%) and the higher return on invested capital (7.84% vs 0.00%). Across the 14 metrics below, ImmuCell Corporation leads on 9 and Cognition Therapeutics, Inc. on 5.

Valuation

Metric CGTX ICCC Biotechnology median
P/E n/m 117.38 7.88
P/S n/m 2.93 11.47
P/B 2.58 2.87 2.52
Price to free cash flow n/m 21.27 21.16
EV/EBITDA n/m 14.22 0.74
EV/Sales n/m 2.92 10.73
Earnings yield (18.09%) 0.85% (28.84%)
Free cash flow yield (20.77%) 4.70% (23.03%)

Profitability

Metric CGTX ICCC Biotechnology median
Gross margin 0.00% 40.32% 65.16%
Operating margin 0.00% 12.60% 0.00%
Net margin 0.00% 2.57% 0.00%
Free cash flow margin 0.00% 13.79% 0.00%
Return on equity (83.76%) 2.57% (57.72%)
Return on assets (57.33%) 1.69% (49.22%)
Return on invested capital 0.00% 7.84% 0.00%

Growth

Metric CGTX ICCC Biotechnology median
Revenue growth (TTM) — 8.49% 5.64%
EPS growth (last fiscal year) 62.79% 53.85% —
Revenue growth, 5-year CAGR — 12.50% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CGTX ICCC Biotechnology median
Debt to equity 0.00 0.26 0.00
Current ratio 7.03 4.75 4.73
Net debt to EBITDA 0.78 1.19 0.96

Dividend

Metric CGTX ICCC Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CGTX ICCC Biotechnology median
Market cap 90.68m 90.55m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack